Acute kidney injury in the patient with cancer
Mitchell H. Rosner1 , Mark A. Perazella2
1Division of Nephrology, University of Virginia Health System, Charlottesville, VA, USA
2Department of Internal Medicine, Section of Nephrology, Yale University School of Medicine, New Haven, CT, USA
Correspondence to: Mitchell H. Rosner
Division of Nephrology, University of Virginia Health System, Charlottesville, VA 22908, USA. E-mail: mhr9r@virginia.edu
Received: April 15, 2019; Revised: May 5, 2019; Accepted: May 13, 2019; Published online: July 9, 2019.
© The Korean Society of Nephrology. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Dramatic advances in the care of patients with cancer have led to significant improvement in outcomes and survival. However, renal manifestations of the underlying cancer as well as the effects of anti-neoplastic therapies leave patients with significant morbidity and chronic kidney disease risks. The most common renal manifestations associated with cancer include acute kidney injury (AKI) in the setting of multiple myeloma, tumor lysis syndrome, post-hematopoietic stem cell therapy, and AKI associated with chemotherapy. Knowledge of specific risk factors, modification of risk and careful attention to rapid AKI diagnosis are critical for improving outcomes.
Keywords: Acute kidney injury, Chemotherapy, Neoplasms, Oncology


e-submission

This Article


Cited By Articles
  • CrossRef (0)
  • PMC (0)
  • SCOPUS (0)

Services
Social Network Service

Archives

Indexed/Covered by